(Q48028662)

English

Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion

scientific article published on 18 April 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16675074

Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16675074

eradication of infectious diseases

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

object named as

W Martin Kast

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16675074

author name string

Pirouz Daftarian

1

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16675074

Marc Mansour

2

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16675074

Anita C Benoit

3

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16675074

Bill Pohajdak

4

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16675074

David W Hoskin

5

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16675074

Robert G Brown

6

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16675074

language of work or name

0 references

publication date

18 April 2006

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16675074

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16675074

24

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16675074

24

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16675074

5235-5244

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16675074

Papillomaviruses and cancer: from basic studies to clinical application

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Prevention of cervical cancer through papillomavirus vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Estimating the world cancer burden: Globocan 2000.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

A controlled trial of a human papillomavirus type 16 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Human papillomavirus vaccine: history, immunology, current status, and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Temporal trends in antibody production in captive grey, harp and hooded seals to a single administration immunocontraceptive vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Immune responses in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Vaccination strategies for the treatment and prevention of cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Toll-like receptors and dendritic cells: for whom the bug tolls

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

On cross-priming of MHC class I-specific CTL: rule or exception?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Therapeutic potential of protein and adjuvant vaccinations on tumour growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Lipid based particulate formulations for the delivery of antigen.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.079

7 January 2021

Identifiers

10.1016/J.VACCINE.2006.03.079

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16675074

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/16675074

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48028662&oldid=2181945946"